Biotechnology
CPHI/ Hi Korea 2026 Opens Pre-Registration: Korea's Hub for Pharma, Biopharma, and Health Innovation
SEOUL, South Korea, June 23, 2026 /PRNewswire/ -- Informa Markets Korea has
officially opened pre-registration for CPHI/ Hi Korea 2026, taking place at
COEX, Seoul, from August 25 to 27. Pre-registered visitors enjoy complimentary
entries.
2026-06-23 08:00
6143
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address ...
2026-06-23 05:37
6914
Texas A&M Study Highlights Pictor PictVet® as a Promising New Tool for Non-Invasive Beef Cattle Health Monitoring
Independent peer-reviewed research published in Frontiers in Veterinary Science reports strong assay performance in a proof-of-concept evaluation using bovine nasopharyngeal swab samples CARLSBAD, Calif., June 23, 2026 /PRNewswire/ -- Pictor Holdings Inc., a global targeted proteomic platform co...
2026-06-23 01:37
3786
CJ BIO to Showcase TasteNrich® Taste Lab for Sodium Reduction, Clean Label, and Taste Design Solutions at IFT FIRST 2026
"Not Just Reducing, But Designing Better Taste" CHICAGO and DOWNERS GROVE, Ill., June 22, 2026 /PRNewswire/ -- CJ BIO will participate in IFT FIRST 2026, taking place July 13–15, 2026, at McCormick Place in Chicago. At Booth #1117, CJ BIO will introduce the TasteNrich® Taste Lab, an application-...
2026-06-22 23:39
5091
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:33
5649
CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
SHANGHAI, June 22, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announced that as informed by the National Medical Products Administration ("NMPA") today, the New Drug Application ("NDA") of sat...
2026-06-22 19:20
4447
ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing
* The total funding comprises US$1 million in angel investment and a US$4 million seed round. The seed financing round was led by Wavemaker Ventures, with participation by SEEDS, further supported by notable investors across the United States and Asia. * The financing will support the continu...
2026-06-22 17:15
3956
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
* Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. * This milestone reflects the Company's long-range quality strategy focused on sustained compl...
2026-06-22 16:57
3738
Innogen Pharmaceutical Group Highlights China-Originated Innovation and Global Development Strategy at DIA Global Annual Meeting 2026 China Town Hall
From original GLP-1 science to international clinical development, Innogen shares its "from 0 to 1" innovation journey in metabolic diseases PHILADELPHIA, June 22, 2026 /PRNewswire/ -- During the DIA Global Annual Meeting 2026 held in Philadelphia, the China Town Hall session was successfully co...
2026-06-22 16:39
3335
Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
— The study shows that EGFR-TKIs induce TROP2 upregulation in DTP cells, providing a mechanistic basis for combining sac-TMT with EGFR-TKI. — The Company is conducting a Phase III registrational study of sac-TMT plus osimertinib as first-line treatment for advanced EGFR-mutant NSCLC (enrollment ...
2026-06-22 14:00
5850
Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research,...
2026-06-22 12:37
5422
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
* ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors * K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China * Antengene r...
2026-06-22 08:30
4880
LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
INCHEON, South Korea and SAN DIEGO, June 21, 2026 /PRNewswire/ -- LOTTE
Biologics announced that it has completed major construction and obtained
approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea.
2026-06-22 08:00
4224
Statement on Novogene Erroneously Listed on 1260H List
BEIJING, June 19, 2026 /PRNewswire/ -- On June 8, 2026, the U.S. Department of Defense (DOD) erroneously designated Novogene Co., Ltd. on its Section 1260H list under the National Defense Authorization Act for Fiscal Year 2021. This designation is factually incorrect. Novogene is an independent,...
2026-06-20 11:21
6883
Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026
SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's global presence and international collaboration at BIO International Convention 2026 (BIO USA), the world's largest biotechnology industry even...
2026-06-19 23:00
4769
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by the Europe...
2026-06-18 12:57
7835
Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
CAMBRIDGE, Mass. and HONG KONG, June 17, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration wit...
2026-06-17 21:00
7459
Gesynta Pharma Randomizes 50% of Patients in Phase 2 Endometriosis Trial of Vipoglanstat
STOCKHOLM, June 17, 2026 /PRNewswire/ -- Gesynta Pharma AB, a Swedish clinical stage pharmaceutical company focusing on chronic inflammatory diseases, today announced that 50% of the target of 190 patients have been randomized in its Phase 2 clinical proof-of-concept trial (NOVA). The study is ev...
2026-06-17 16:06
5629
Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at the 2026 European Hem...
2026-06-17 13:39
5113
Dioseve Secures JPY 1.45 Billion to Advance iPS Cell‑Based IVF Support, Adds TIME100 Scientist as Advisor
Funding round and NEDO Deep Tech Startup Support Program selection will support development and clinical adoption of DIOS‑101, an iPS cell‑derived co‑culture designed to reduce the burden of IVF treatment. TOKYO, June 16, 2026 /PRNewswire/ -- Dioseve Inc. ("Dioseve"), a Tokyo-based fertility bio...
2026-06-17 00:00
5327
Week's Top Stories
Most Reposted
Agoda and Singapore Tourism Board Expand Partnership to Boost Demand and Tech Transformation in Tourism
[Picked up by 314 media titles]
2026-08-14 10:00
Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
PARKROYAL COLLECTION Marina Bay, Singapore Named Among Singapore's Top 10 Hotels by Travel + Leisure and Featured on 50 Best Discovery
[Picked up by 313 media titles]
2026-08-14 12:27
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 295 media titles]
2026-08-13 23:42Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
17738
Two CityUHK scholars elected to the European Academy of Engineering in recognition of their internationally acclaimed research achievements
2026-08-10 19:12
14926
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
2026-08-12 16:02
8888